An expert argues that existing data, based on short-term studies, grossly underappreciates the value of lung screening for SCLC. In clinical practice, robust, ongoing screening programs are diagnosing approximately 60% of SCLC cases in the limited stage, dramatically improving the potential for curative-intent therapy.

A practical, gold-standard clinical test for oncologists to quickly screen for LEMS is to ask a patient to stand from a chair without using their arms. An inability to do so is a strong, immediate indicator of proximal leg weakness—a hallmark of LEMS—and should trigger a more comprehensive workup.

Despite updated NCCN guidelines and the availability of a simple blood test, real-world data shows persistently low screening rates for LEMS. This massive diagnostic gap means the vast majority of SCLC patients suffering from this debilitating syndrome are not being identified or treated for it.

To effectively diagnose LEMS, healthcare systems must implement systemic changes rather than relying on individual clinician awareness. This includes using tumor boards for unexplained weakness, treating VGCC results as critical lab values requiring a direct handoff, and building bundled order sets for testing and referrals to create a reliable diagnostic pathway.

Experts express concern that the paraneoplastic syndrome LEMS is frequently missed in SCLC patients. Its primary symptom, proximal muscle weakness, is often attributed to the cancer itself or treatment side effects, leading clinicians to overlook the specific diagnostic test for this distinct and potentially treatable condition.

Lambert-Eaton Myasthenic Syndrome (LEMS) frequently develops before its associated cancer is detected. This makes recognizing its key symptoms, like proximal muscle weakness, a critical opportunity for early cancer screening and intervention, which can significantly improve patient outcomes.

Oncologists should be highly suspicious of LEMS when a patient's functional decline is disproportionate to their cancer's response to treatment. If imaging shows tumors are shrinking but the patient is getting weaker, this mismatch is a critical signal that a distinct paraneoplastic process is at play and warrants immediate investigation.

Oncologists can differentiate LEMS from general cancer fatigue by assessing if neurologic complaints, like difficulty rising from a chair, are disproportionate to the disease burden visible on scans. This clinical heuristic is a powerful, low-tech tool to trigger suspicion and further testing for LEMS.

Symptomatic treatment for LEMS, such as with amifampridine (Firdapse), is not just for quality of life. Its primary strategic goal is to optimize a patient's performance status, making them strong enough to tolerate more aggressive and effective cancer-directed treatments like chemotherapy and immunotherapy, which can improve overall cancer outcomes.